CA3217141A1 - Dosing regimen for combination therapy targeting dll3 and pd-1 - Google Patents

Dosing regimen for combination therapy targeting dll3 and pd-1 Download PDF

Info

Publication number
CA3217141A1
CA3217141A1 CA3217141A CA3217141A CA3217141A1 CA 3217141 A1 CA3217141 A1 CA 3217141A1 CA 3217141 A CA3217141 A CA 3217141A CA 3217141 A CA3217141 A CA 3217141A CA 3217141 A1 CA3217141 A1 CA 3217141A1
Authority
CA
Canada
Prior art keywords
dll3
dose
administered
agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3217141A
Other languages
English (en)
French (fr)
Inventor
Nooshin Hashemi SADRAEI
Aditya SHETTY
Mukul MINOCHA
Marie-Ann Damiette Smit
Hansen Wong
Siddhartha ROYCHOUDHURY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3217141A1 publication Critical patent/CA3217141A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3217141A 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1 Pending CA3217141A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163186569P 2021-05-10 2021-05-10
US63/186,569 2021-05-10
PCT/US2022/028135 WO2022240688A1 (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1

Publications (1)

Publication Number Publication Date
CA3217141A1 true CA3217141A1 (en) 2022-11-17

Family

ID=84029376

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3217141A Pending CA3217141A1 (en) 2021-05-10 2022-05-06 Dosing regimen for combination therapy targeting dll3 and pd-1

Country Status (12)

Country Link
US (1) US20240317856A1 (enExample)
EP (1) EP4337252A4 (enExample)
JP (1) JP2024518947A (enExample)
KR (1) KR20240006585A (enExample)
CN (1) CN117377488A (enExample)
AU (1) AU2022273509A1 (enExample)
CA (1) CA3217141A1 (enExample)
CL (1) CL2023003357A1 (enExample)
IL (1) IL307646A (enExample)
MX (1) MX2023013227A (enExample)
TW (1) TW202309092A (enExample)
WO (1) WO2022240688A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP4482586A1 (en) * 2022-02-23 2025-01-01 Amgen Inc. Cancer treatment targeting dll3
KR20250116698A (ko) * 2022-12-08 2025-08-01 암젠 인크 Dll3-발현 암의 치료 방법
CN121620371A (zh) * 2023-05-19 2026-03-06 勃林格殷格翰国际公司 T细胞衔接蛋白在治疗癌症中的用途
CN120168667B (zh) * 2025-03-18 2026-04-14 中国科学院近代物理研究所 一种多肽在制备dll3过度表达的肿瘤的特异性靶向分子探针中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI793062B (zh) * 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
EA039859B1 (ru) * 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
CR20200539A (es) * 2018-04-10 2021-07-01 Kite Pharma Inc Receptores quiméricos de dll3 y métodos para su uso
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白

Also Published As

Publication number Publication date
CN117377488A (zh) 2024-01-09
US20240317856A1 (en) 2024-09-26
MX2023013227A (es) 2024-01-29
IL307646A (en) 2023-12-01
EP4337252A1 (en) 2024-03-20
AU2022273509A1 (en) 2023-10-19
KR20240006585A (ko) 2024-01-15
WO2022240688A1 (en) 2022-11-17
TW202309092A (zh) 2023-03-01
EP4337252A4 (en) 2025-04-23
JP2024518947A (ja) 2024-05-08
CL2023003357A1 (es) 2024-06-07

Similar Documents

Publication Publication Date Title
US20240317856A1 (en) Dosing regimen for combination therapy targeting dll3 and pd-1
AU2020276242B2 (en) Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer
US20200277398A1 (en) Humanized antibodies against ceacam1
JP7709434B2 (ja) 抗ｄｌｌ３剤の投与レジメン
WO2018133842A1 (zh) 人程序性死亡受体pd-1的单克隆抗体及其片段
CA3252459A1 (en) DLL3 TARGETED CANCER TREATMENT
CN119095619A (zh) 抗cd19药剂的剂量方案及其用途
US20240010729A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist and lenvatinib or a pharmaceutically acceptable salt thereof for treating patients with cancer
CN120529917A (zh) 使用抗CTLA4抗体与Pembrolizumab组合治疗癌症的方法
WO2023208990A1 (en) Combination therapy for the treatment of cancer comprising a fas axis antagonist and a t-reg cell depleting agent antagonist,
CN118785922A (zh) 靶向dll3的癌症治疗
US20230265196A1 (en) Combination Therapy of a PD-1 Antagonist and an Antagonist for VEGFR-2 for Treating Patients with Cancer
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
EA051285B1 (ru) Схема введения доз комбинированной терапии, нацеливающейся на dll3 и pd-1
EA051880B1 (ru) Схема введения доз для средств на основе антитела к dll3
WO2025054110A1 (en) Combination therapy of a pd-1 antagonist and lag3 antagonist for treating patients with cancer before and/or after surgery
KR20250075750A (ko) 항-ctla4 항체를 사용한 암의 치료 방법
WO2026060304A1 (en) Subcutaneous administration of anti-dll3 agent for treatment of cancer
CN110845614A (zh) 人细胞表面免疫调节分子

Legal Events

Date Code Title Description
R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241125

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241125

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241220

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250424

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250424

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260421

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260421